Skip to main content

Table 2 Demographics, clinical activity measures and IP-10 analysis of localized scleroderma (LS) patients and controls (psoriasis and healthy) participating in tissue analysis

From: Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma

Clinical and laboratory features of tissue analyses subjects LS subjects Healthy controls Psoriasis controls
(number = 5) (number = 2) (number = 2)
Demographic information Number (%) Number (%) Number (%)
  Female 4 (80) 1 (50) 2 (100)
  Ethnicity:    
   Caucasian 5 (100) 1 (50) 2 (100)
   African American --- 1 (50) ---
  Subtype:    
   Linear (trunk/limb) 3 (60) --- ---
   Plaque (circumscribed superficial) 2 (40) --- ---
  Age Median (IQR) Ages in years Ages in years
   Age at onset, years 13 (6 to 16) --- ---
   Age at biopsy, years 13 (10 to 16) 17, 18 34, 47
Tissue analysis Number (%) Number (%) Number (%)
  IP-10 staining present in cellular infiltrate 5 (100) 0 (0) 2 (100)
  Degree of cellular infiltratea    
   Mild (1 to 50) 3 (60) 2 (100) 0 (0)
   Moderate (51 to 150) 2 (40) 0 (0) 2 (100)
Clinical measures and plasma IP-10 of LS patientsb Median (IQR)   
   PGA-A 48 (41 to 52) --- ---
   mLoSSI 7 (7 to 8) --- ---
   Plasma level of IP-10 (pg/ml)c 2,814 (745 to 3,081) --- ---
  1. aAverage cellular infiltrate in skin: out of three high power fields: 1 to 50 = mild; 51 to 150 = moderate; >150 severe; bclinical and plasma measures obtained at first pediatric rheumatology visit, which was within 12 weeks of the biopsy date; cdetermined by Luminex assay. IP-10, interferon-gamma inducible protein-10; IQR, interquartile range; mLoSSI, modified Localized Scleroderma Skin Score; PGA-A, physicians global assessment of activity.